Rev3l-KO Mouse
Common Name
Rev3l-KO
제품 ID
S-KO-19277
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-19714-Rev3l-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Rev3l-KO Mouse (카탈로그 번호 S-KO-19277)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Rev3l-KO
품종 계통계통 ID
KOCMP-19714-Rev3l-B6J-VB
유전자명
제품 ID
S-KO-19277
유전자 별칭
Rev, Rev3, Sez4
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 10
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000019986
NCBI 전사체 ID
NM_011264
타겟 영역
Exon 11
유효 영역 크기
~1.6 kb
유전자 연구 개요
REV3L, also known as Protein reversion less 3-like, encodes the catalytic subunit of error-prone translesion synthesis polymerase ζ. This polymerase is involved in the DNA damage tolerance mechanism of translesion synthesis (TLS), which allows DNA replication to proceed past DNA lesions. TLS is crucial for maintaining genome stability in the face of DNA damage [1,2,3,4,5,6].
In non-small cell lung cancer (NSCLC), certain single nucleotide variants in REV3L (rs1002481, rs462779, rs465646) are significantly associated with an increased risk of the disease under the recessive model, suggesting its potential as a genetic predisposition marker [1]. In NSCLC H1299 cells, cisplatin treatment induces REV3L expression. Overexpression of REV3L confers resistance to cisplatin, while knockdown sensitizes the cells, indicating it can be a novel target for NSCLC chemotherapy [2]. Similar roles in chemoresistance are seen in esophageal squamous cell carcinoma, gliomas, and cervical cancer. In esophageal squamous cell carcinoma, REV3L is upregulated, and its downregulation decreases cell proliferation, invasive capacity, and increases sensitivity to 5-fluorouracil [3]. In gliomas, REV3L overexpression attenuates cisplatin-induced apoptosis, and RNAi-mediated downregulation enhances cisplatin sensitivity [4]. In cervical cancer, suppression of REV3L enhances cisplatin sensitivity, while overexpression confers resistance [5]. A homozygous ultra-rare REV3L variant (T2753R) in a child is associated with developmental delay, hypotrophy, and dysmorphic features, and in yeast, an equivalent mutation shows dysfunction of TLS in the nucleus and instability of mitochondrial genetic information [6]. A c.9253-6T>C REV3L mutation in a myelodysplastic syndrome patient is associated with poor prognosis [7]. In NSCLC, circular RNA PRMT5 promotes cisplatin resistance via the miR-4458/REV3L axis [8]. MAD2L2 promotes replication fork protection and recovery in a REV3L-dependent manner [9].
In conclusion, REV3L is essential for translesion synthesis and genome stability. Its role in various cancers, such as NSCLC, esophageal squamous cell carcinoma, gliomas, and cervical cancer, highlights its significance in cancer development and chemoresistance. The discovery of its association with developmental disorders and myelodysplastic syndrome also broadens our understanding of its impact on human health. Studies on REV3L contribute to uncovering disease mechanisms and may provide new therapeutic targets.
References:
1. Jamwal, Rajeshwer Singh, Mahajan, Nikita, Bhat, Gh Rasool, Kumar, Rakesh, Bhat, Audesh. 2021. REV3L single nucleotide variants lead to increased susceptibility towards non-small cell lung cancer in the population of Jammu and Kashmir. In Cancer epidemiology, 75, 102047. doi:10.1016/j.canep.2021.102047. https://pubmed.ncbi.nlm.nih.gov/34655923/
2. Wang, Wenjie, Sheng, Wenjiong, Yu, Chenxiao, Zhang, Huojun, Zhang, Shuyu. 2015. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells. In Oncology reports, 34, 1460-8. doi:10.3892/or.2015.4121. https://pubmed.ncbi.nlm.nih.gov/26165320/
3. Zhu, Xiaozhong, Zou, Shitao, Zhou, Jundong, Wu, Jinchang, Chen, Yihong. 2016. REV3L, the catalytic subunit of DNA polymerase ζ, is involved in the progression and chemoresistance of esophageal squamous cell carcinoma. In Oncology reports, 35, 1664-70. doi:10.3892/or.2016.4549. https://pubmed.ncbi.nlm.nih.gov/26752104/
4. Wang, Huibo, Zhang, Shu-Yu, Wang, Shuai, Lu, Daru, Zhao, Shiguang. . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. In Neuro-oncology, 11, 790-802. doi:10.1215/15228517-2009-015. https://pubmed.ncbi.nlm.nih.gov/19289490/
5. Yang, Li, Shi, Tingyan, Liu, Fei, Yang, Gong, Cheng, Xi. 2015. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. In PloS one, 10, e0120334. doi:10.1371/journal.pone.0120334. https://pubmed.ncbi.nlm.nih.gov/25781640/
6. Halas, Agnieszka, Fijak-Moskal, Jolanta, Kuberska, Renata, Sledziewska-Gojska, Ewa, Płoski, Rafał. 2021. Developmental delay with hypotrophy associated with homozygous functionally relevant REV3L variant. In Journal of molecular medicine (Berlin, Germany), 99, 415-423. doi:10.1007/s00109-020-02033-3. https://pubmed.ncbi.nlm.nih.gov/33474647/
7. Oliveira, Roberta Taiane G de, França, Ivo Gabriel F, Junior, Howard L R, Magalhães, Silvia M M, Pinheiro, Ronald F. 2020. c.9253-6T>c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome. In Hematology, transfusion and cell therapy, 43, 377-381. doi:10.1016/j.htct.2020.05.006. https://pubmed.ncbi.nlm.nih.gov/32682781/
8. Pang, Jun, Ye, Liwen, Zhao, Dan, Zhao, Ding, Chen, Qingwei. 2020. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. In Cell biology international, 44, 2416-2426. doi:10.1002/cbin.11449. https://pubmed.ncbi.nlm.nih.gov/32808744/
9. Paniagua, Inés, Tayeh, Zainab, Falcone, Mattia, Cerutti, Aurora, Jacobs, Jacqueline J L. 2022. MAD2L2 promotes replication fork protection and recovery in a shieldin-independent and REV3L-dependent manner. In Nature communications, 13, 5167. doi:10.1038/s41467-022-32861-5. https://pubmed.ncbi.nlm.nih.gov/36075897/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
